Novel and proprietary CAR-T approach
holds potential to be first effective CAR-T therapy for solid
tumors
SAN
JOSE, Calif., May 21, 2024
/PRNewswire/ -- Anixa Biosciences,
Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer, today announced that treatment has commenced
for the fifth patient in its ongoing Phase 1 clinical trial of its
novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian
cancer. The study is being conducted through a research partnership
with Moffitt Cancer Center.
Anixa's first-in-human trial (NCT05316129) is enrolling female
adult patients with recurrent/progressing ovarian cancer who were
unresponsive to at least two prior therapies. Safety was confirmed
in the first three-patient cohort. The patients in the second
cohort, including patient #5, receive triple the dose of engineered
T-cells compared with the first cohort of three patients. The study
will identify the maximum tolerated dose of T-cells targeting the
follicle stimulating hormone receptor (FSHR), found only on ovarian
cells
"With our fifth patient treated, our trial is progressing, and
we continue to see that our therapy appears to be safe and
well-tolerated," said Dr. Amit
Kumar, Chairman and CEO of Anixa. "The technology behind our
novel CAR-T therapy differs from traditional CAR-T therapies by
targeting the FSHR, which research indicates is exclusively
expressed on ovarian cells in healthy adult females. We developed
this approach to tackle preexisting difficulties with CAR-T cell
therapies in solid ovarian tumors. In our trial, we will also
explore several parameters for applying our CAR-T therapy to solid
tumors in general."
Anixa's FSHR-mediated CAR-T technology was developed by
Jose R. Conejo-Garcia, M.D., Ph.D.,
Professor of Immunology in the Department of Integrative
Immunobiology at the Duke University
School of Medicine. Anixa holds an exclusive world-wide license to
the technology from The Wistar Institute.
About Anixa's CER-T Approach (Follicle Stimulating Hormone
Receptor-Mediated CAR-T technology)
Anixa's chimeric antigen
receptor T-cell (CAR-T) technology approach is an autologous cell
therapy comprised of engineered T-cells that target the follicle
stimulating hormone receptor (FSHR). FSHR is found at
immunologically relevant levels exclusively on the granulosa cells
of the ovaries. Since the target is a hormone (chimeric endocrine)
receptor, and the target-binding domain is derived from its natural
ligand, this technology is known as CER-T (chimeric endocrine
receptor T-cell) therapy, a new type of CAR-T.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor T-cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to
prevent breast cancer – specifically triple
negative breast cancer
(TNBC), the most lethal form of the disease –
and ovarian cancer, as well as additional cancer vaccines to
address many intractable cancers, including high incidence
malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn,
Facebook and YouTube.
Forward-Looking Statements: Statements that are
not historical fact may be considered forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements are not statements of
historical facts, but rather reflect Anixa's current expectations
concerning future events and results. We generally use the words
"believes," "expects," "intends," "plans," "anticipates," "likely,"
"will" and similar expressions to identify forward-looking
statements. Such forward-looking statements, including those
concerning our expectations, involve risks, uncertainties and other
factors, some of which are beyond our control, which may cause our
actual results, performance or achievements, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward- looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html
SOURCE Anixa Biosciences, Inc.